Vinkovci

Researchers are evaluating whether a medicine called BI 764198 helps adults and adolescents with certain kidney conditions, including secondary focal segmental glomerulosclerosis, treatment-resistant primary minimal change disease, Alport Syndrome, and treatment-resistant primary membranous nephropathy. The study is a Phase II, randomized, double-blind, placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics, and efficacy of BI 764198 in these proteinuric kidney diseases. Participants are randomly assigned to one of two groups, with twice the chance of receiving BI 764198 compared to placebo. They take one tablet daily for 20 weeks while continuing their standard kidney disease medications. The study lasts about seven months, during which participants attend six in-person visits and have three phone calls. The trial includes multiple cohorts based on specific kidney conditions. During the study, doctors regularly collect urine samples to measure protein levels and blood samples to monitor kidney function. Researchers compare these results between the treatment and placebo groups to evaluate changes in proteinuria and kidney filtration rate. Participants health and any side effects are closely monitored throughout the trial.